Prescient Therapeutics Ltd (PTX) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Prescient Therapeutics Ltd A$0.03, price A$0.07, upside -57.0%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Prescient Therapeutics Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range A$0.0370 – A$0.3000 · the A$0.0670 price screens above the A$0.0288 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Prescient Therapeutics in your weekly email
Every Wednesday you see whether Prescient Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1.
Show more
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Stock analysis
Prescient Therapeutics Ltd (PTX) currently trades at A$0.0670, while our model-based Fair Value estimate is A$0.0288, implying the stock looks roughly 132.6% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Prescient Therapeutics Ltd reported revenue of A$4.4M in FY2025 versus A$1.2M in FY2021, a compound +38.5%/yr. Reported net income was −A$7.3M in FY2025.
Key figures
Market cap A$80.4M (≈ $56.6M) · P/S ratio 18.0 · EPS (TTM) A$−0.0100 · Net margin −208% · Return on equity −54.3% · Return on assets (EBIT) −37.7% · Operating margin −344% · Revenue (TTM) A$4.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 34 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and 63% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −57%, PTX screens richer than that median.
Fair Value models
Bear A$0.0288Fair Value A$0.0288Bull A$0.0288
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+17.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.5%
Start year 2020 (pandemic). Over 10 years: +59.9% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.7%
’05
’07
’08
’15
’17
’18
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−436.7% (2020) → −173.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Prescient Therapeutics Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside−57% · Below median
Profitability
Return on assets−32% · Bottom 25%
Net margin (TTM)−168% · Bottom 25%
Growth and dividend
Revenue growth−7% · Below median
Balance sheet
Debt / equity0.08× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B4.97× · Priciest 25%
P/S (TTM)13.28× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)96· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Prescient Therapeutics Ltd (PTX) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of A$0.0288 versus a price of A$0.0670, about −57% upside (overvalued).
What is the fair value of PTX?
Our model-based fair value for Prescient Therapeutics Ltd is A$0.0288 (as of Sep 23, 2026), built from audited fundamentals. The current price: A$0.0670.
What is the quality score of PTX?
Prescient Therapeutics Ltd has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Prescient Therapeutics Ltd (PTX)?
Our model-based price target is the fair value of A$0.0288 (as of Sep 23, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Prescient Therapeutics Ltd stock forecast for 2026?
Our models put fair value at A$0.0288, about −57% upside versus a price of A$0.0670 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Prescient Therapeutics Ltd (PTX)?
Prescient Therapeutics Ltd reported trailing-twelve-month revenue of about A$4.3M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Prescient Therapeutics Ltd (PTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Prescient Therapeutics Ltd it is A$0.0288 per share (as of Sep 23, 2026), against a price of A$0.0670. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Prescient Therapeutics Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, PTX trades above its calculated fair value: price A$0.0670, fair value A$0.0288, a gap of about −57% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PTX?
No. The price is what the market pays today (A$0.0670); the fair value is what the company's own numbers justify (A$0.0288). For Prescient Therapeutics Ltd the two are A$0.0382 per share apart. That gap is exactly why we show both numbers side by side.
How much is Prescient Therapeutics Ltd worth?
The market values Prescient Therapeutics Ltd at about A$80.4M (market capitalisation, as of Sep 23, 2026). Per share that is A$0.0670; our models calculate a fair value of A$0.0288 per share.
How solid is the balance sheet of Prescient Therapeutics Ltd (PTX)?
Balance-sheet figures for Prescient Therapeutics Ltd (as of Sep 23, 2026): return on equity −54.3%, debt of 0.08 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is PTX from its 52-week high?
Prescient Therapeutics Ltd trades at A$0.0670, about 36% below its 52-week high of A$0.1050 and 63% above the low of A$0.0410 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0288 is for.
Which stocks are comparable to Prescient Therapeutics Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Prescient Therapeutics Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price A$0.0670, calculated fair value A$0.0288 (−57%), Quality Score 54/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PTX calculated?
We run Prescient Therapeutics Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.0288, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Prescient Therapeutics Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Prescient Therapeutics Ltd (PTX)?
The closing price on Sep 23, 2026 was A$0.0670. Our model-based fair value is A$0.0288, about −57% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Prescient Therapeutics Ltd right now?
The price sits above even our optimistic bull case (A$0.0288). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Prescient Therapeutics Ltd
How large is the market capitalisation of Prescient Therapeutics Ltd (PTX)?
The market capitalisation of Prescient Therapeutics Ltd is A$80.4M (≈ $56.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Prescient Therapeutics Ltd (PTX)?
The price-to-sales ratio of Prescient Therapeutics Ltd is 18.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Prescient Therapeutics Ltd (PTX)?
Earnings per share at Prescient Therapeutics Ltd are A$−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Prescient Therapeutics Ltd (PTX)?
The net margin of Prescient Therapeutics Ltd is −208% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Prescient Therapeutics Ltd (PTX)?
The return on equity (ROE) of Prescient Therapeutics Ltd is −54.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Prescient Therapeutics Ltd (PTX)?
On an EBIT basis the return on assets of Prescient Therapeutics Ltd is −37.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Prescient Therapeutics Ltd (PTX)?
The operating margin of Prescient Therapeutics Ltd is −344% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Prescient Therapeutics Ltd (PTX)?
Revenue at Prescient Therapeutics Ltd is growing −7.3% versus a year earlier (3y avg +32.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Prescient Therapeutics Ltd (PTX) generate?
The free cash flow of Prescient Therapeutics Ltd is −A$7.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Prescient Therapeutics Ltd (PTX) hold?
Prescient Therapeutics Ltd holds more cash than debt, A$6.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Prescient Therapeutics Ltd in the live analysis
One click puts Prescient Therapeutics Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
